| Literature DB >> 17913308 |
V A Feodorova1, L N Pan'kina, E P Savostina, L V Sayapina, V L Motin, S V Dentovskaya, R Z Shaikhutdinova, S A Ivanov, B Lindner, A N Kondakova, O V Bystrova, N A Kocharova, S N Senchenkova, O Holst, G B Pier, Y A Knirel, A P Anisimov.
Abstract
The lpxM mutant of the live vaccine Yersinia pestis EV NIIEG strain synthesising a less toxic penta-acylated lipopolysaccharide was found to be avirulent in mice and guinea pigs, notably showing no measurable virulence in Balb/c mice which do retain some susceptibility to the parental strain itself. Twenty-one days after a single injection of the lpxM-mutant, 85-100% protection was achieved in outbred mice and guinea pigs, whereas a 43% protection rate was achieved in Balb/c mice given single low doses (10(3) to 2.5 x 10(4) CFU) of this vaccine. A subcutaneous challenge with 2000 median lethal doses (equal to 20,000 CFU) of fully virulent Y. pestis 231 strain, is a 6-10-fold higher dose than that which the EV NIIEG itself can protect against.Entities:
Mesh：
Substances：
Year: 2007 PMID： 17913308 DOI： 10.1016/j.vaccine.2007.08.055
Source DB: PubMed Journal: Vaccine ISSN： 0264-410X Impact factor: 3.641